DK1044969T3 - Fremgangsmåde og mellemprodukter til fremstilling af anti-cancer forbindelser - Google Patents
Fremgangsmåde og mellemprodukter til fremstilling af anti-cancer forbindelserInfo
- Publication number
- DK1044969T3 DK1044969T3 DK00302256T DK00302256T DK1044969T3 DK 1044969 T3 DK1044969 T3 DK 1044969T3 DK 00302256 T DK00302256 T DK 00302256T DK 00302256 T DK00302256 T DK 00302256T DK 1044969 T3 DK1044969 T3 DK 1044969T3
- Authority
- DK
- Denmark
- Prior art keywords
- intermediates
- preparation
- cancer compounds
- cancer
- compounds
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B15/00—Obtaining copper
- C22B15/0002—Preliminary treatment
- C22B15/0004—Preliminary treatment without modification of the copper constituent
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
- C22B15/00—Obtaining copper
- C22B15/0063—Hydrometallurgy
- C22B15/0065—Leaching or slurrying
- C22B15/0067—Leaching or slurrying with acids or salts thereof
- C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P10/00—Technologies related to metal processing
- Y02P10/20—Recycling
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Metallurgy (AREA)
- Mechanical Engineering (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12707299P | 1999-03-31 | 1999-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1044969T3 true DK1044969T3 (da) | 2007-04-23 |
Family
ID=22428179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00302256T DK1044969T3 (da) | 1999-03-31 | 2000-03-20 | Fremgangsmåde og mellemprodukter til fremstilling af anti-cancer forbindelser |
Country Status (50)
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
RU2264389C3 (ru) | 2000-10-20 | 2018-06-01 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения |
WO2003000188A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
AU2003249212C1 (en) | 2002-07-15 | 2011-10-27 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
US7148231B2 (en) * | 2003-02-17 | 2006-12-12 | Hoffmann-La Roche Inc. | [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph |
EP1604665B1 (en) | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase inhibitor |
JP5129957B2 (ja) | 2003-07-03 | 2013-01-30 | ミリアド ジェネティクス, インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘発因子としての4−アリールアミノ−キナゾリン |
US8309562B2 (en) * | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
MXPA06002964A (es) | 2003-09-16 | 2006-06-14 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de cinasa de tirosina. |
SI2392564T1 (sl) | 2003-09-26 | 2014-02-28 | Exelixis, Inc. | c-Met modulatorji in postopki uporabe |
CN100450998C (zh) | 2003-11-11 | 2009-01-14 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
BRPI0510604B8 (pt) * | 2004-05-06 | 2021-05-25 | Warner Lambert Co | composto 4-fenilamino-quinazolin-6-il-amida, seu uso e composição farmacêutica que o compreende composto 4-fenilamino-quinazolin-6-il-amida, seu uso e composição farmacêutica que o compreende |
WO2006030826A1 (ja) | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | 医薬組成物 |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
US7625911B2 (en) * | 2005-01-12 | 2009-12-01 | Mai De Ltd. | Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion |
CA2599115A1 (en) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | Novel combinational use of sulfonamide compound |
JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
CA2627598C (en) * | 2005-11-07 | 2013-06-25 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
EP1964837A4 (en) * | 2005-11-22 | 2010-12-22 | Eisai R&D Man Co Ltd | Antitumor agent against multiple myeloma |
CA2652442C (en) * | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
EP2044939A1 (en) * | 2006-06-29 | 2009-04-08 | Eisai R&D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
CA2659307A1 (en) | 2006-07-28 | 2008-01-31 | Synthon B.V. | Crystalline erlotinib |
KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
US8372856B2 (en) * | 2006-10-27 | 2013-02-12 | Synthon Bv | Hydrates of erlotinib hydrochloride |
KR20090108086A (ko) | 2007-01-19 | 2009-10-14 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 췌장암 치료용 조성물 |
WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
PT2170844T (pt) * | 2007-02-21 | 2016-08-05 | Natco Pharma Ltd | Novos polimorfos de cloridrato de erlotinib e método de preparação |
NZ579997A (en) | 2007-04-04 | 2012-08-31 | Cipla Ltd | PROCESS FOR PREPARATION OF N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
WO2009002538A2 (en) * | 2007-06-25 | 2008-12-31 | Plus Chemicals S.A. | Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib |
WO2009007984A2 (en) | 2007-07-11 | 2009-01-15 | Hetero Drugs Limited | An improved process for erlotinib hydrochloride |
US20090124642A1 (en) * | 2007-08-23 | 2009-05-14 | Augusto Canavesi | Crystalline forms of Erlotinib HCI and formulations thereof |
TW200927732A (en) * | 2007-08-23 | 2009-07-01 | Plus Chemicals S A | Crystalline forms of erlotinib HCl and formulations thereof |
US20090076042A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched erlotinib |
CA2704000C (en) | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
WO2009096377A1 (ja) * | 2008-01-29 | 2009-08-06 | Eisai R & D Management Co., Ltd. | 血管阻害物質とタキサンとの併用 |
CN102083801A (zh) * | 2008-03-28 | 2011-06-01 | 康瑟特制药公司 | 喹唑啉衍生物和治疗方法 |
CA2730226A1 (en) * | 2008-07-07 | 2010-01-14 | Plus Chemicals Sa | Crystalline forms of erlotinib base and erlotinib hcl |
KR101132937B1 (ko) | 2008-10-01 | 2012-04-06 | 주식회사종근당 | N-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염 |
WO2010040212A1 (en) * | 2008-10-08 | 2010-04-15 | Apotex Pharmachem Inc. | Processes for the preparation of erlotinib hydrochloride |
CN110818633A (zh) | 2009-01-16 | 2020-02-21 | 埃克塞里艾克西斯公司 | 一种苹果酸盐及其晶型 |
CN102438995B (zh) | 2009-03-26 | 2014-12-17 | 兰贝克赛实验室有限公司 | 厄洛替尼或其药学上可接受的盐的制备工艺 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
EP2499118A2 (en) | 2009-11-12 | 2012-09-19 | Ranbaxy Laboratories Limited | Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b |
WO2011068404A2 (en) | 2009-12-02 | 2011-06-09 | Ultimorphix Technologies B.V. | Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation |
CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
CA2806273A1 (en) | 2010-07-23 | 2012-03-08 | Generics (Uk) Limited | Pure erlotinib |
IT1402029B1 (it) * | 2010-10-14 | 2013-08-28 | Italiana Sint Spa | Procedimento per la preparazione di erlotinib |
WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
ES2705950T3 (es) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
CN102267952B (zh) * | 2011-06-21 | 2013-12-11 | 天津市汉康医药生物技术有限公司 | 喹唑啉类化合物、其制备方法和用途 |
CN103420924B (zh) * | 2012-05-25 | 2016-08-31 | 浙江九洲药业股份有限公司 | 一种盐酸埃罗替尼晶型a的制备方法 |
WO2014037961A1 (en) | 2012-09-04 | 2014-03-13 | Shilpa Medicare Limited | Crystalline erlotinib hydrochloride process |
US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
WO2014118737A1 (en) | 2013-01-31 | 2014-08-07 | Ranbaxy Laboratories Limited | Erlotinib salts |
ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
CN103333124B (zh) * | 2013-05-28 | 2015-03-25 | 埃斯特维华义制药有限公司 | 一种制备盐酸厄洛替尼晶型f的方法 |
KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
CA2908441A1 (en) | 2014-10-28 | 2016-04-28 | Cerbios-Pharma Sa | Process for the preparation of erlotinib |
US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
KR102587702B1 (ko) | 2015-08-20 | 2023-10-12 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양 치료제 |
CN105884653A (zh) * | 2016-06-08 | 2016-08-24 | 浙江汇能生物股份有限公司 | 一种埃罗替尼衍生物及其制备方法 |
CN106279585A (zh) * | 2016-08-26 | 2017-01-04 | 宁波圣达精工智能科技有限公司 | 一种阻燃智能密集书架的制备方法 |
JP2020519576A (ja) | 2017-05-16 | 2020-07-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝細胞癌の治療 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4747498A (en) * | 1986-06-27 | 1988-05-31 | Sunbeam Plastics Corporation | Safety dispensing closure-container package |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
JP2657760B2 (ja) * | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | 4−アミノキナゾリン誘導体およびそれを含有する医薬品 |
DE69536015D1 (de) * | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
ATE237596T1 (de) | 1996-02-13 | 2003-05-15 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
PT885198E (pt) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
US6225499B1 (en) | 1997-07-14 | 2001-05-01 | Catalytica Pharmaceuticals, Inc. | Process for preparing aminoarylacetylenes |
MEP42008A (en) | 1998-04-29 | 2011-02-10 | Osi Farmaceuticals Inc | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
-
2000
- 2000-03-03 RS YUP-132/00A patent/RS49836B/sr unknown
- 2000-03-03 YU YU13200A patent/YU13200A/sh unknown
- 2000-03-10 OA OA1200000071A patent/OA11335A/en unknown
- 2000-03-14 CR CR6165A patent/CR6165A/es unknown
- 2000-03-17 PA PA20008491901A patent/PA8491901A1/es unknown
- 2000-03-20 AT AT00302256T patent/ATE348098T1/de not_active IP Right Cessation
- 2000-03-20 DE DE60032275T patent/DE60032275T2/de not_active Expired - Lifetime
- 2000-03-20 PT PT00302256T patent/PT1044969E/pt unknown
- 2000-03-20 EP EP00302256A patent/EP1044969B1/en not_active Expired - Lifetime
- 2000-03-20 ES ES00302256T patent/ES2278578T3/es not_active Expired - Lifetime
- 2000-03-20 DK DK00302256T patent/DK1044969T3/da active
- 2000-03-21 IS IS5411A patent/IS2468B/is unknown
- 2000-03-22 CO CO00020444A patent/CO5160273A1/es unknown
- 2000-03-23 IL IL13524500A patent/IL135245A0/xx not_active IP Right Cessation
- 2000-03-23 IL IL168036A patent/IL168036A/en not_active IP Right Cessation
- 2000-03-27 SK SK444-2000A patent/SK287339B6/sk not_active IP Right Cessation
- 2000-03-27 UA UA2000031727A patent/UA70928C2/uk unknown
- 2000-03-27 ID IDP20000240A patent/ID25427A/id unknown
- 2000-03-27 EG EG20000364A patent/EG22506A/xx active
- 2000-03-27 SG SG200302185A patent/SG115536A1/en unknown
- 2000-03-27 UA UA20040503766A patent/UA80955C2/uk unknown
- 2000-03-27 SG SG200001746A patent/SG121687A1/en unknown
- 2000-03-27 BR BRPI0001486A patent/BRPI0001486B8/pt not_active IP Right Cessation
- 2000-03-27 TW TW089105605A patent/TW553939B/zh not_active IP Right Cessation
- 2000-03-28 AU AU22620/00A patent/AU781402B2/en not_active Expired
- 2000-03-28 BG BG104278A patent/BG65194B1/bg unknown
- 2000-03-29 CA CA002302965A patent/CA2302965C/en not_active Expired - Lifetime
- 2000-03-29 MY MYPI20001252A patent/MY136270A/en unknown
- 2000-03-29 UY UY26086A patent/UY26086A1/es not_active Application Discontinuation
- 2000-03-29 AP APAP/P/2000/001778A patent/AP1265A/en active
- 2000-03-29 MA MA25940A patent/MA25087A1/fr unknown
- 2000-03-29 ZA ZA200001586A patent/ZA200001586B/xx unknown
- 2000-03-29 TN TNTNSN00064A patent/TNSN00064A1/fr unknown
- 2000-03-29 AR ARP000101413A patent/AR018705A1/es active IP Right Grant
- 2000-03-29 AP APAP/P/2003/002757D patent/AP1655A/en active
- 2000-03-29 CA CA002427221A patent/CA2427221C/en not_active Expired - Lifetime
- 2000-03-29 JP JP2000091300A patent/JP3420549B2/ja not_active Expired - Lifetime
- 2000-03-29 DZ DZ000059A patent/DZ3030A1/xx active
- 2000-03-30 EA EA200201245A patent/EA005892B1/ru not_active IP Right Cessation
- 2000-03-30 NZ NZ503683A patent/NZ503683A/en not_active IP Right Cessation
- 2000-03-30 NO NO20001648A patent/NO321952B1/no not_active IP Right Cessation
- 2000-03-30 EE EEP200000255A patent/EE04589B1/xx not_active IP Right Cessation
- 2000-03-30 TR TR2000/00837A patent/TR200000837A2/xx unknown
- 2000-03-30 US US09/538,635 patent/US6476040B1/en not_active Expired - Lifetime
- 2000-03-30 NZ NZ512818A patent/NZ512818A/xx not_active IP Right Cessation
- 2000-03-30 HU HU0001353A patent/HU227698B1/hu unknown
- 2000-03-30 PL PL00339330A patent/PL339330A1/xx not_active Application Discontinuation
- 2000-03-30 PE PE2000000277A patent/PE20001599A1/es not_active Application Discontinuation
- 2000-03-30 KR KR1020000016386A patent/KR100430210B1/ko active IP Right Grant
- 2000-03-30 EA EA200201244A patent/EA005561B1/ru not_active IP Right Cessation
- 2000-03-30 GT GT200000037A patent/GT200000037A/es unknown
- 2000-03-30 EA EA200000274A patent/EA004654B1/ru not_active IP Right Cessation
- 2000-03-30 SV SV2000000047A patent/SV2002000047A/es not_active Application Discontinuation
- 2000-03-30 CZ CZ20001155A patent/CZ299426B6/cs not_active IP Right Cessation
- 2000-03-31 GE GEAP20005284A patent/GEP20022653B/en unknown
- 2000-03-31 CN CNB001045954A patent/CN1215061C/zh not_active Expired - Lifetime
- 2000-03-31 CN CNB2005100763600A patent/CN100351242C/zh not_active Expired - Lifetime
- 2000-03-31 HR HR20000182A patent/HRP20000182B1/xx not_active IP Right Cessation
-
2001
- 2001-01-27 HK HK01100595A patent/HK1029790A1/xx not_active IP Right Cessation
-
2002
- 2002-07-29 KR KR10-2002-0044610A patent/KR100430209B1/ko active IP Right Grant
- 2002-12-12 JP JP2002360742A patent/JP4074509B2/ja not_active Expired - Lifetime
-
2005
- 2005-04-08 AU AU2005201494A patent/AU2005201494B2/en not_active Expired
- 2005-10-13 NO NO20054715A patent/NO324745B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1044969T3 (da) | Fremgangsmåde og mellemprodukter til fremstilling af anti-cancer forbindelser | |
DK1173431T3 (da) | Fremgangsmåde til fremstilling af citalopram | |
DK1105382T3 (da) | Fremgangsmåde til fremstilling af citalopram | |
DK1296935T3 (da) | Fremgangsmåde til fremstilling af substituerede octanoylamider | |
DK1159274T3 (da) | Fremgangsmåde til fremstilling af citalopram | |
DK1165576T3 (da) | Fremgangsmåde til fremstilling af amin-platin-komplekser | |
DK1309581T3 (da) | Fremgangsmåde til fremstilling af citalopram | |
DK1328538T3 (da) | Fremgangsmåde og mellemprodukter til fremstilling af 7-substituerede antiöstrogener | |
DK1407037T3 (da) | Fremgangsmåde til fremstilling af tagatose | |
DK1147075T3 (da) | Fremgangsmåde til fremstilling af L-phenylephrinhydrochlorid | |
DK1187833T3 (da) | Fremgangsmåde til fremstilling af thiamethoxam | |
DK1028960T3 (da) | Fremgangsmåde til fremstilling af thiazolidinedion | |
DK1326836T3 (da) | Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin | |
DK1296970T3 (da) | Fremgangsmåde til fremstilling af citalopram | |
DK1228056T3 (da) | Fremgangsmåde til fremstilling af citalopram | |
DK1511724T3 (da) | Fremgangsmåde til fremstilling af thioalkylaminderivater | |
DK1177165T3 (da) | Fremgangsmåde til fremstilling af pesticidmellemprodukter | |
DK1519936T3 (da) | Fremgangsmåde til fremstilling af nevirapin | |
DK1254159T3 (da) | Fremgangsmåde til fremstilling af acetylamidiniophenylalanylcyclohexylglycylpyridylalaninamider | |
DK1012152T3 (da) | Fremgangsmåde til fremstilling af oxazaphosphorin-2-aminer | |
DK1165483T3 (da) | Fremgangsmåde til fremstilling af carbonylfluorid | |
DK1073627T3 (da) | Fremgangsmåde til fremstilling af pesticidmellemprodukter | |
DK1029867T3 (da) | Fremgangsmåde til fremstilling af organiske azider | |
DK1670773T3 (da) | Fremgangsmåde til fremstilling af benzoxazol-sulfonamidforbindelser og mellemprodukter deraf | |
DK0930297T3 (da) | Fremgangsmåde til fremstilling af naphtyridoner og mellemprodukter |